Description
The Q1695X likely pathogenic variant in the SCN5A gene has been published previously in association with Brugada syndrome and cardiac conduction disease (CCD) (Meregalli et al., 2009; Kapplinger et al., 2010; Béziau et al., 2014). Meregalli et al. (2009) reported Q1695X in one individual with either Brugada syndrome or progressive CCD, and Kapplinger et al. (2010) reported this variant in two unrelated individuals with a suspected diagnosis of Brugada syndrome; detailed clinical information for patients harboring this variant was not provided by either study. Béziau et al. (2014) identified Q1695X in a 22 year-old male proband with a clinical history of Brugada syndrome, CCD, shortened QTc interval (<360ms), and aborted sudden cardiac death; the affected proband also harbored a missense variant in the CACNA1C gene. A variety of cardiac phenotypes were observed in this family, as well as a third variant in the ABCC9 gene; however, Q1695X was shown to specifically segregate with CCD (Béziau et al., 2014). Q1695X is predicted to cause loss of normal protein function via truncation of the final 322 amino acids of the protein product. Multiple other nonsense variants in the SCN5A gene (including several downstream of Q1695X) have been reported in Human Gene Mutation Database in association with Brugada syndrome, CCD, LQTS, and Sudden unexplained death (Stenson et al., 2014). Furthermore, the Q1695X variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server)
| # | Sample | Method | Observation |
|---|
| Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
|---|
| 1 | germline | yes | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |
